• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

[Long-term safety and efficacy of high-dose cytarabine consolidation in patients with acute myeloid leukemia].

作者信息

Cao X X, Wang S J, Duan M H, Zhu T N, Zhang W, Han B, Zhuang J L, Cai H C, Chen M, Feng J, Han X, Zhang Y, Yang C, Zhang L, Zhou D B, Li J

出版信息

Zhonghua Xue Ye Xue Za Zhi. 2017 Apr 14;38(4):330-333. doi: 10.3760/cma.j.issn.0253-2727.2017.04.013.

DOI:10.3760/cma.j.issn.0253-2727.2017.04.013
PMID:28468096
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7342724/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0e9a/7342724/0e6ddb5b21c7/cjh-38-04-330-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0e9a/7342724/0e6ddb5b21c7/cjh-38-04-330-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0e9a/7342724/0e6ddb5b21c7/cjh-38-04-330-g001.jpg

相似文献

1
[Long-term safety and efficacy of high-dose cytarabine consolidation in patients with acute myeloid leukemia].[大剂量阿糖胞苷巩固治疗急性髓系白血病患者的长期安全性和疗效]
Zhonghua Xue Ye Xue Za Zhi. 2017 Apr 14;38(4):330-333. doi: 10.3760/cma.j.issn.0253-2727.2017.04.013.
2
Transplantation of autologous peripheral blood progenitor cells procured after high-dose cytarabine-based consolidation chemotherapy for adults with secondary acute myelogenous leukemia in first remission.大剂量阿糖胞苷巩固化疗后采集的自体外周血祖细胞移植用于首次缓解期的成人继发性急性髓系白血病患者。
Leuk Lymphoma. 1999 May;33(5-6):475-84. doi: 10.3109/10428199909058452.
3
[Efficacy and safety of induction chemotherapy consisting of anthracycline for 3 days and cytarabine for 7 days in elderly patients with acute myeloid leukemia].[蒽环类药物连用3天及阿糖胞苷连用7天的诱导化疗方案治疗老年急性髓系白血病的疗效与安全性]
Gan To Kagaku Ryoho. 2007 Oct;34(10):1617-21.
4
The efficacy and safety of daunorubicin versus idarubicin combined with cytarabine for induction therapy in acute myeloid leukemia: A meta-analysis of randomized clinical trials.柔红霉素与伊达比星联合阿糖胞苷用于急性髓性白血病诱导治疗的疗效与安全性：一项随机临床试验的荟萃分析
Medicine (Baltimore). 2020 Jun 12;99(24):e20094. doi: 10.1097/MD.0000000000020094.
5
A randomized trial of high-versus conventional-dose cytarabine in consolidation chemotherapy for adult de novo acute myeloid leukemia in first remission after induction therapy containing high-dose cytarabine.一项关于高剂量与常规剂量阿糖胞苷用于巩固化疗的随机试验，该巩固化疗针对接受含高剂量阿糖胞苷诱导治疗后首次缓解的成年初治急性髓细胞白血病患者。
Blood. 2005 Jan 15;105(2):481-8. doi: 10.1182/blood-2004-01-0326. Epub 2004 Jun 22.
6
Sense and nonsense of high-dose cytarabine for acute myeloid leukemia.大剂量阿糖胞苷治疗急性髓系白血病的合理与不合理之处。
Blood. 2013 Jan 3;121(1):26-8. doi: 10.1182/blood-2012-07-444851.
7
Efficacy and safety of consolidation therapy with intermediate and high dose cytarabine in acute myeloid leukemia patients.中高剂量阿糖胞苷巩固治疗急性髓系白血病患者的疗效和安全性。
Hematology. 2021 Dec;26(1):355-364. doi: 10.1080/16078454.2021.1912949.
8
[A Retrospective Study on the Efficacy and Safety of Idarubicin Combined with High-Dose Cytarabine Consolidation in Patients with Acute Myeloid Leukemia over 60 Years of Age in First Remission].伊达比星联合大剂量阿糖胞苷巩固治疗60岁以上初治急性髓系白血病患者缓解后疗效及安全性的回顾性研究
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2023 Jun;31(3):671-676. doi: 10.19746/j.cnki.issn.1009-2137.2023.03.009.
9
Does high-dose cytarabine cause cumulative toxicity in patients undergoing consolidation therapy for acute myeloid leukemia?大剂量阿糖胞苷对接受急性髓系白血病巩固治疗的患者是否会产生累积毒性？
Am J Hematol. 2013 Jun;88(6):533-4. doi: 10.1002/ajh.23440. Epub 2013 May 2.
10
High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial.高剂量阿糖胞苷诱导治疗可改善年龄<46 岁成人急性髓系白血病患者的预后：EORTC-GIMEMA AML-12 试验结果。
J Clin Oncol. 2014 Jan 20;32(3):219-28. doi: 10.1200/JCO.2013.51.8571. Epub 2013 Dec 2.

引用本文的文献

1
Intermediate dose cytarabine improves survival and relapse-free rate compared with standard-dose cytarabine as post-remission treatment for acute myeloid leukemia: A retrospection study.中剂量阿糖胞苷作为急性髓系白血病缓解后治疗优于标准剂量阿糖胞苷：回顾性研究。
Medicine (Baltimore). 2021 Jan 22;100(3):e24273. doi: 10.1097/MD.0000000000024273.
2
Safety and Feasibility of Outpatient High Dose Cytarabine for Acute Myeloid Leukemia in the Brazilian Amazon.巴西亚马逊地区门诊高剂量阿糖胞苷治疗急性髓系白血病的安全性和可行性
Int J Hematol Oncol Stem Cell Res. 2020 Jul 1;14(3):151-156. doi: 10.18502/ijhoscr.v14i3.3722.

本文引用的文献

1
Comparison of consolidation strategies in acute myeloid leukemia: high-dose cytarabine alone versus intermediate-dose cytarabine combined with anthracyclines.急性髓系白血病巩固治疗策略的比较：单纯大剂量阿糖胞苷与中剂量阿糖胞苷联合蒽环类药物的对比
Ann Hematol. 2015 Sep;94(9):1485-92. doi: 10.1007/s00277-015-2389-9. Epub 2015 May 6.
2
Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia.欧洲白血病网络标准化系统报告成人急性髓细胞白血病细胞遗传学和分子改变的预后意义。
J Clin Oncol. 2012 Dec 20;30(36):4515-23. doi: 10.1200/JCO.2012.43.4738. Epub 2012 Sep 17.
3
NCCN Clinical Practice Guidelines Acute myeloid leukemia.
NCCN 临床实践指南：急性髓系白血病。
J Natl Compr Canc Netw. 2012 Aug;10(8):984-1021. doi: 10.6004/jnccn.2012.0103.
4
Acute myeloid leukemia in the real world: why population-based registries are needed.真实世界中的急性髓细胞白血病：为什么需要基于人群的登记处。
Blood. 2012 Apr 26;119(17):3890-9. doi: 10.1182/blood-2011-12-379008. Epub 2012 Mar 1.
5
Comparison of high-dose cytarabine and timed-sequential chemotherapy as consolidation for younger adults with AML in first remission: the ALFA-9802 study.高剂量阿糖胞苷与时间序列化疗作为首次缓解的年轻 AML 患者巩固治疗的比较：ALFA-9802 研究。
Blood. 2011 Aug 18;118(7):1754-62. doi: 10.1182/blood-2011-04-349258. Epub 2011 Jun 20.
6
Cytarabine dose of 36 g/m² compared with 12 g/m² within first consolidation in acute myeloid leukemia: results of patients enrolled onto the prospective randomized AML96 study.在急性髓细胞白血病首次强化治疗中，阿糖胞苷剂量 36g/m² 与 12g/m² 比较：前瞻性随机 AML96 研究入组患者的结果。
J Clin Oncol. 2011 Jul 1;29(19):2696-702. doi: 10.1200/JCO.2010.33.7303. Epub 2011 May 23.
7
Attempts to optimize induction and consolidation treatment in acute myeloid leukemia: results of the MRC AML12 trial.尝试优化急性髓细胞白血病的诱导和巩固治疗：MRC AML12 试验的结果。
J Clin Oncol. 2010 Feb 1;28(4):586-95. doi: 10.1200/JCO.2009.22.9088. Epub 2009 Dec 28.
8
Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: the EORTC and GIMEMA Groups Study AML-10.柔红霉素与米托蒽醌和伊达比星对比作为成人急性髓系白血病的诱导和巩固化疗：EORTC 和 GIMEMA 组 AML-10 研究。
J Clin Oncol. 2009 Nov 10;27(32):5397-403. doi: 10.1200/JCO.2008.20.6490. Epub 2009 Oct 13.
9
Anthracycline dose intensification in acute myeloid leukemia.急性髓系白血病中蒽环类药物剂量强化
N Engl J Med. 2009 Sep 24;361(13):1249-59. doi: 10.1056/NEJMoa0904544.
10
[The efficacy of high-dose cytarabine for patients with t(8;21) AML and with normal karyotype AML].[大剂量阿糖胞苷对t(8;21)急性髓系白血病及核型正常急性髓系白血病患者的疗效]
Zhonghua Xue Ye Xue Za Zhi. 2008 Feb;29(2):110-2.